Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
9,878 total articles
aTyr Pharma CEO Shukla Sanjay sold 3,745 shares on Feb. 4, 2026 to satisfy tax withholding associated with vested restricted stock units, after receiving 10,375 shares on Feb. 3, 2026. The company, with a market capitalization of $86.28 million, is trading slightly below its fair value while reporting that it holds more cash than debt but is rapidl…
Todd Watanabe, President and CEO of Arcutis Biotherapeutics (NASDAQ: ARQT), sold 19,833 shares on February 2, 2026, for $505,709 to satisfy tax withholding tied to restricted stock units. The transaction leaves Watanabe with 721,306 directly held shares and several additional holdings held indirectly through trusts and an LLC. The company has poste…
UroGen Pharma Ltd's Chief Medical Officer, Mark Schoenberg, sold 7,373 ordinary shares on February 3, 2026, at $19.69 apiece to satisfy withholding tax tied to settled restricted stock units. The company recently reported third-quarter 2025 results that missed consensus on earnings per share and revenue, and no analyst actions or M&A updates have b…
Adaptive Biotechnologies Chief Executive and Chairman Chad M. Robins sold 124,998 shares on February 2, 2026, for about $2.3 million under a Rule 10b5-1 plan. The transaction coincides with a year of notable revenue gains for the company and strategic agreements with Pfizer, though valuation metrics and negative EBITDA highlight ongoing financial c…
Director Peter A. Thompson reported the sale of Sionna Therapeutics stock across two days in early February 2026, totaling $1.37 million. The transactions occurred at prices between $44.57 and $44.58 per share. The company has recently drawn contrasting analyst views: Raymond James has raised its price target and kept a Strong Buy, while RBC Capita…
Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 42,788 shares across February 2 and 3, 2026, realizing approximately $799,104. The transactions were carried out under a Rule 10b5-1 plan and occurred as the company reported significant 2025 revenue gains and announced strategic collaborations and financing activity.
Chief Financial Officer Daniella Beckman sold 10,317 shares of Tango Therapeutics (NASDAQ: TNGX) on February 3, 2026, realizing roughly $126,530. The disposals, reported on a Form 4 with the Securities and Exchange Commission, were executed in two transactions and were disclosed as tax-withholding sales tied to restricted stock unit vesting. The co…
Christopher S. Ziluca, chief credit officer at Hancock Whitney Corp (HWC), sold 5,227 shares on January 23, 2026, for $68.57 per share, totaling $358,415. After the sale and a domestic-relations transfer, Ziluca directly holds 33,301.4529 shares. The transaction comes amid Hancock Whitney’s fourth-quarter 2025 results that showed a slight earnings-…
Jeffrey P. Klenk, Executive Vice President of Travelers Companies (TRV), sold 16,712 shares on January 23, 2026, for roughly $4.6 million at an average price of $279.7746. On the same day he exercised options to acquire 16,712 shares in two tranches, with exercise prices of $140.85 and $132.58, totaling $2,256,299. The company recently reported ope…
MapLight Therapeutics director Robert C. Malenka sold 7,040 shares of the company's Voting Common Stock on February 2-3, 2026, at prices between $18.00 and $18.02 per share, producing proceeds of $126,860. After the transactions, Malenka directly holds 358,233 shares and indirectly holds 31,672 shares via a living trust. The company has reported fa…
Lemonade CEO Daniel A. Schreiber sold 9,108 shares on January 23, 2026, for roughly $902,056 under a pre-arranged Rule 10b5-1 plan. The stock traded at $99.04 at the time - close to its 52-week high - and has since retreated to $74.18. The company faces several near-term events, including an earnings release and the scheduled expiration of warrants…
Esther Rajavelu, who serves as Chief Executive Officer, Chief Financial Officer and Chief Business Officer at Spero Therapeutics (NASDAQ: SPRO), sold 18,442 shares on February 2, 2026 to satisfy tax withholding tied to vested restricted stock units, while also receiving a grant of restricted stock units and stock options the same day. The company r…
Natera President and CEO Steven Leonard Chapman sold 89,324 shares of common stock across February 2 and 3, 2026, generating roughly $20.7 million in proceeds at prices between $229.0846 and $234.00 per share. The transactions, disclosed on a Form 4 filing, were executed under a Rule 10b5-1 plan adopted in December 2023 and amended in December 2024…
Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), sold 4,639 shares of common stock on February 2nd and 3rd, 2026, under a Rule 10b5-1 trading plan, generating $1,072,537 in proceeds. The transactions occurred while Natera shares have shown notable six-month gains but recent short-term weakness. The company conti…
On February 2, 2026, CoreWeave CROWV Chief Development Officer Brannin McBee, via family trusts, sold 34,831 shares of Class A common stock for roughly $3.19 million under a Rule 10b5-1 plan adopted November 17, 2025. The company’s shares have since fallen to $82.46, down 17.15% over the prior week, even as a large NVIDIA equity investment and seve…
Natera Inc. President and Chief Business Officer John Fesko sold 3,594 shares of Natera stock on February 3, 2026, in two transactions totaling $830,278. The sales, executed under a Rule 10b5-1 trading plan to satisfy tax liabilities tied to vested restricted stock units granted in 2025 and 2026, leave Fesko with 178,081 shares. The transactions co…
Daniel Rabinowitz, Natera's Secretary and Chief Legal Officer, sold 1,334 shares on February 3, 2026, to meet tax obligations tied to RSU vesting. The transaction left him with 223,813 shares. Separately, Natera reported preliminary fourth-quarter results showing near 40% revenue growth and about 17% higher test volume, and advanced regulatory and …
Bank of America sold a small parcel of ENvue Medical stock on February 2, 2026, trimming part of its indirect position while remaining a large shareholder. The move was disclosed in an SEC Form 4. ENvue, recently rebranded from NanoVibronix and trading as FEED on Nasdaq, has announced commercial hires, a national distribution agreement for its ENFi…
East West Bancorp INC Chief Executive Officer Ng Dominic sold 50,000 shares on February 4, 2026, totaling $5.89 million. The trades were executed in two blocks at prices between $117.62 and $118.07 while EWBC traded close to a 52-week high. The move follows quarterly results that beat expectations and came amid analyst price-target adjustments.
Barbara Weber, identified as a director and Executive Chair of Tango Therapeutics (NASDAQ: TNGX), disposed of 30,519 shares on February 3, 2026 in two transactions totaling roughly $374,293. The move follows an equity award the prior day and occurs amid corporate developments including a $100 million at-the-market offering, a Stifel Buy rating with…
FiscalNote Holdings director Tim Hwang sold 4,090 Class A common shares on February 2, 2026, in two transactions under a Rule 10b5-1 plan, realizing roughly $4,900 to satisfy tax obligations tied to vested restricted stock units. The transaction occurred while the company’s shares trade near a 52-week low and the firm reports solid gross margins an…
Arcutis Biotherapeutics CFO Latha Vairavan sold 1,320 shares on Feb. 2, 2026 to satisfy tax withholding tied to restricted stock units. The transaction, totaling $33,657, comes as the company reports positive Phase 2 results for ZORYVE in infants, changes to its promotion arrangement, a board appointment, and an FDA acceptance for a pediatric psori…
Arcutis Biotherapeutics director Howard G. Welgus sold 10,000 shares on February 2, 2026, in transactions that generated roughly $250,483. The sales were executed through a 10b5-1 trading plan established in March 2025. The company meanwhile reported positive Phase 2 data for ZORYVE in infants, transitioned promotion responsibilities in-house, appo…
Alphatec Holdings Executive Vice President of People & Culture Craig E. Hunsaker sold 37,358 shares on February 3, 2026 under a pre-arranged Rule 10b5-1 trading plan to cover tax obligations tied to vested restricted stock units. The company posted preliminary fourth-quarter and full-year 2025 results that modestly beat expectations, but the stock …
Arista Networks director Charles H. Giancarlo sold 7,900 shares of the company's common stock on February 2, 2026 under a Rule 10b5-1 trading plan, generating $1.12 million. The sales were executed at weighted average prices between $138.9082 and $141.9373 per share, above the company's current trading price of $130.28. Arista, valued at $164.56 bi…
